✦ LIBER ✦

Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease A double-blind crossover trial.

✍ Scribed by J. Presthus; J. Berstad; K. Lien

Book ID: 114782429
Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 267 KB
Volume: 76
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1987.tb03567.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Deprenyl (selegiline) combined with levo

Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease

✍ JAN PRESTHUS; ALAJOS HAJBA 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

Double-blind, crossover placebo controll

Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease — an interim analysis

✍ P. F. Teychenne; S. Parker 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB

Impact of sustained deprenyl (selegiline

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

✍ Ira Shoulson; David Oakes; Stanley Fahn; Anthony Lang; J. William Langston; Pete 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 3 views

Double-blind trial of levodopa/carbidopa

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

✍ Robert A. Hauser; Michel Panisset; Giovanni Abbruzzese; Linda Mancione; Nalina D 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

## Abstract We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patie

Selegiline as the primary treatment of P

Selegiline as the primary treatment of Parkinson's disease — a long-term double-blind study

✍ V. V. Myllylä; K. A. Sotaniemi; P. Hakulinen; O. Mäki-lkola; E. H. Heinonen 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 739 KB

Comparison of orally dissolving carbidop

Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial

✍ William G. Ondo; Lina Shinawi; Steven Moore 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Levodopa use in fluctuating Parkinson's disease (PD) is complicated by an inconsistent and prolonged onset to clinical improvement. An orally dissolved carbidopa/levodopa (OD C/L) preparation (Parcopa UCB Pharma) is available in the United States. This offers potential advantages to sho